LOGIN  |  REGISTER
Chimerix

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 130.98
1.28 0.99
10.19M
1.73B
US$ 226.600B
US$ 482.74
1.40 0.29
1.56M
356.18M
US$ 171.940B
US$ 427.50
-9.29 -2.13
3.00M
382.50M
US$ 163.520B
US$ 95.12
-0.13 -0.14
6.56M
1.47B
US$ 139.830B
US$ 186.83
-3.83 -2.01
3.58M
722.28M
US$ 134.940B
US$ 346.50
-0.17 -0.05
1.32M
381.22M
US$ 132.090B
US$ 82.60
-0.10 -0.12
5.61M
1.28B
US$ 105.730B
US$ 697.08
2.38 0.34
995,853
126.94M
US$ 88.490B
US$ 198.71
-1.69 -0.84
4.02M
290.01M
US$ 57.630B
US$ 92.54
0.49 0.53
981,495
494.60M
US$ 45.770B
US$ 71.53
0.33 0.46
3.01M
589.80M
US$ 42.190B
US$ 411.49
9.11 2.26
952,396
81.88M
US$ 33.690B
US$ 134.71
0.35 0.26
2.13M
242.01M
US$ 32.600B
US$ 212.91
1.42 0.67
1.06M
146.80M
US$ 31.260B
US$ 102.48
-33.62 -24.70
1.72M
285.60M
US$ 29.270B
US$ 68.57
-0.16 -0.23
3.59M
390.60M
US$ 26.780B
US$ 143.91
-4.53 -3.05
3.26M
181.50M
US$ 26.120B
US$ 222.23
2.21 1.00
440,424
98.71M
US$ 21.940B
US$ 1.00
-11.69 -1.15
209,770
21.10M
US$ 21.200B
US$ 148.08
-2.09 -1.39
578,493
132.02M
US$ 19.550B
US$ 97.92
0.98 1.01
4.30M
199.07M
US$ 19.490B
US$ 321.01
-0.09 -0.03
421,182
59.38M
US$ 19.060B
US$ 163.80
-0.67 -0.41
1.48M
111.62M
US$ 18.280B
US$ 217.12
-3.45 -1.56
750,058
83.64M
US$ 18.160B
US$ 246.80
-3.93 -1.57
589,917
70.14M
US$ 17.310B
US$ 79.51
1.28 1.64
2.06M
199.58M
US$ 15.870B
US$ 28.89
1.07 3.85
5.27M
510.59M
US$ 14.750B
US$ 201.90
-7.23 -3.46
1.66M
72.42M
US$ 14.620B
US$ 57.56
1.06 1.88
6.46M
225.72M
US$ 12.990B
US$ 139.32
-4.22 -2.94
1.75M
82.56M
US$ 11.500B
US$ 25.93
0.24 0.93
687,508
435.99M
US$ 11.310B
US$ 71.20
-2.33 -3.17
2.60M
158.60M
US$ 11.290B
US$ 91.82
-1.93 -2.06
1.32M
121.70M
US$ 11.170B
US$ 277.35
-0.44 -0.16
319,885
38.38M
US$ 10.640B
US$ 296.28
-0.22 -0.07
696,457
31.08M
US$ 9.210B
US$ 40.71
-0.73 -1.76
1.71M
222.26M
US$ 9.050B
US$ 152.15
0.47 0.31
447,594
53.54M
US$ 8.150B
US$ 71.01
-0.13 -0.18
554,774
113.74M
US$ 8.080B
US$ 41.58
-0.68 -1.61
3.12M
185.08M
US$ 7.700B
US$ 130.00
-2.10 -1.59
739,959
56.03M
US$ 7.280B
US$ 101.32
0.80 0.80
408,155
69.53M
US$ 7.040B
US$ 40.45
-0.41 -1.00
4.55M
152.40M
US$ 6.160B
US$ 129.48
1.27 0.99
459,397
46.44M
US$ 6.010B
US$ 44.97
-0.21 -0.46
1.80M
123.56M
US$ 5.560B
US$ 36.28
-1.46 -3.87
3.43M
151.60M
US$ 5.500B
US$ 238.18
-7.03 -2.87
228,960
22.92M
US$ 5.460B
US$ 106.05
1.80 1.73
1.61M
51.14M
US$ 5.420B
US$ 90.89
0.32 0.35
619,280
58.28M
US$ 5.300B
US$ 90.26
1.46 1.64
651,543
55.14M
US$ 4.980B
US$ 79.97
0.00 0.00
0
58.56M
US$ 4.680B
US$ 150.21
3.30 2.25
598,548
29.97M
US$ 4.500B
US$ 12.06
0.21 1.77
838,696
352.16M
US$ 4.250B
US$ 80.28
0.48 0.60
285,668
49.41M
US$ 3.970B
US$ 116.98
0.77 0.66
806,507
33.54M
US$ 3.920B
US$ 49.78
-0.74 -1.46
691,130
74.03M
US$ 3.690B
US$ 70.98
0.00 0.00
0
51.11M
US$ 3.630B
US$ 138.67
-0.47 -0.34
201,140
24.48M
US$ 3.390B
US$ 99.90
-0.05 -0.05
251,818
31.30M
US$ 3.130B
US$ 10.48
-0.01 -0.10
834,189
283.24M
US$ 2.970B
US$ 88.24
2.86 3.35
960,508
33.56M
US$ 2.960B
US$ 53.03
0.22 0.42
847,821
54.11M
US$ 2.870B
US$ 57.17
0.28 0.49
545,948
50.22M
US$ 2.870B
US$ 36.80
-1.65 -4.29
726,130
59.58M
US$ 2.190B
US$ 86.28
1.61 1.90
182,235
22.48M
US$ 1.940B
US$ 35.58
0.51 1.45
599,848
54.30M
US$ 1.930B
US$ 15.58
-0.25 -1.58
696,787
108.20M
US$ 1.690B
US$ 25.17
-0.10 -0.40
910,990
67.26M
US$ 1.690B
US$ 32.01
-0.07 -0.22
442,969
48.75M
US$ 1.560B
US$ 10.56
0.33 3.23
2.14M
141.77M
US$ 1.500B
US$ 48.59
0.56 1.17
383,307
30.89M
US$ 1.500B
US$ 14.26
0.00 0.00
3.19M
101.66M
US$ 1.450B
US$ 9.55
-0.01 -0.10
1.34M
128.36M
US$ 1.230B
US$ 15.83
0.08 0.51
416,470
77.16M
US$ 1.220B
US$ 25.25
-0.25 -0.98
860,080
45.69M
US$ 1.150B
US$ 14.92
0.01 0.07
841,026
76.25M
US$ 1.140B
US$ 16.86
-0.40 -2.32
943,013
65.68M
US$ 1.110B
US$ 13.09
0.00 0.00
16.57M
83.72M
US$ 1.100B
US$ 17.74
0.85 5.03
123,205
61.52M
US$ 1.090B
US$ 21.93
-0.15 -0.68
304,997
49.60M
US$ 1.090B
US$ 7.79
-0.03 -0.38
1.49M
134.56M
US$ 1.050B
US$ 21.91
-0.35 -1.57
531,362
46.39M
US$ 1.020B
US$ 6.68
0.05 0.75
357,075
146.95M
US$ 981.630M
US$ 1.43
0.01 0.70
1.82M
672.80M
US$ 962.100M
US$ 22.93
-0.15 -0.65
241,463
41.92M
US$ 961.230M
US$ 4.39
-0.21 -4.57
12.32M
216.94M
US$ 952.370M
US$ 17.62
-0.60 -3.29
512,969
53.63M
US$ 944.960M
US$ 27.00
0.50 1.89
623,356
33.60M
US$ 907.200M
US$ 31.45
1.27 4.21
552,727
28.76M
US$ 904.500M
US$ 16.89
0.75 4.65
468,469
49.28M
US$ 832.340M
US$ 7.64
-0.27 -3.41
1.57M
91.04M
US$ 695.550M
US$ 15.57
-0.01 -0.06
477,888
44.01M
US$ 685.240M
US$ 51.77
-0.19 -0.37
30,344
12.67M
US$ 655.930M
US$ 21.51
0.25 1.18
445,939
28.01M
US$ 602.500M
US$ 11.01
0.10 0.92
113,210
52.94M
US$ 582.870M
US$ 14.43
-0.09 -0.62
902,545
40.30M
US$ 581.530M
US$ 13.85
0.52 3.90
388,579
41.94M
US$ 580.870M
US$ 12.43
0.37 3.07
449,773
45.96M
US$ 571.280M
US$ 4.05
0.00 0.00
86,544
139.82M
US$ 566.270M
US$ 17.86
-0.46 -2.51
266,908
30.59M
US$ 546.340M
US$ 6.93
0.16 2.36
1.15M
77.11M
US$ 534.370M
US$ 14.85
0.36 2.48
615,948
35.82M
US$ 531.750M
US$ 7.82
0.04 0.51
304,811
65.37M
US$ 511.190M
US$ 21.00
0.41 1.99
101,768
24.22M
US$ 508.620M
US$ 13.03
0.07 0.54
243,210
38.21M
US$ 497.880M
US$ 3.65
-0.02 -0.54
416,673
128.81M
US$ 470.160M
US$ 2.34
-0.01 -0.43
2.11M
186.64M
US$ 436.740M
US$ 1.16
0.03 2.65
689,162
372.26M
US$ 431.820M
US$ 11.63
0.08 0.69
305,473
36.20M
US$ 421.010M
US$ 6.45
-0.07 -1.07
392,034
62.30M
US$ 401.840M
US$ 27.57
-0.57 -2.03
45,985
14.29M
US$ 393.980M
US$ 9.52
0.06 0.63
466,392
40.47M
US$ 385.270M
US$ 0.60
0.0059 0.99
2.26M
595.33M
US$ 357.200M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 1.17
-0.03 -2.50
3.97M
294.32M
US$ 344.350M
US$ 10.79
0.36 3.45
167,044
29.85M
US$ 322.080M
US$ 13.33
-0.02 -0.15
122,764
24.00M
US$ 319.920M
US$ 5.20
0.70 15.56
4.18M
58.52M
US$ 304.300M
US$ 7.32
0.16 2.23
821,744
41.23M
US$ 301.800M
US$ 32.49
1.48 4.77
312,016
9.27M
US$ 301.140M
US$ 3.13
0.14 4.68
521,179
92.44M
US$ 289.340M
US$ 2.61
0.06 2.35
468,029
105.48M
US$ 275.300M
US$ 9.39
0.14 1.51
102,603
27.60M
US$ 259.160M
US$ 6.63
0.06 0.91
180,487
38.94M
US$ 258.170M
US$ 29.48
0.79 2.75
38,497
8.74M
US$ 257.660M
US$ 5.15
-0.01 -0.19
802,156
49.57M
US$ 255.290M
US$ 10.54
0.01 0.09
80,500
23.48M
US$ 247.480M
US$ 9.21
0.19 2.11
132,244
26.22M
US$ 241.490M
US$ 28.00
0.00 0.00
0
8.53M
US$ 238.840M
C$ 0.82
0.00 0.00
66,736
282.82M
C$ 231.910M
US$ 6.04
0.02 0.33
80,838
37.43M
US$ 225.890M
US$ 2.99
0.07 2.40
703,278
74.59M
US$ 223.020M
US$ 5.84
0.00 0.00
0
37.47M
US$ 218.820M
US$ 3.76
-0.01 -0.27
301,132
55.65M
US$ 209.240M
US$ 60.83
-0.50 -0.82
31,211
3.26M
US$ 198.310M
US$ 22.79
0.12 0.53
56,165
8.46M
US$ 192.800M
US$ 4.56
-0.23 -4.80
345,734
39.49M
US$ 180.070M
US$ 52.30
-0.10 -0.19
11,092
3.39M
US$ 177.300M
US$ 5.74
0.01 0.17
15,581
30.49M
US$ 175.010M
US$ 4.95
0.42 9.27
938,219
34.82M
US$ 172.360M
US$ 6.82
-0.06 -0.87
218,379
23.82M
US$ 162.450M
US$ 13.88
0.13 0.95
89,795
11.61M
US$ 161.150M
US$ 1.15
-0.01 -0.86
1.61M
138.40M
US$ 159.160M
US$ 1.85
0.06 3.35
343,429
84.73M
US$ 156.750M
US$ 8.24
-0.11 -1.32
27,030
18.82M
US$ 155.080M
US$ 6.25
0.10 1.63
240,821
24.26M
US$ 151.620M
US$ 1.48
0.02 1.37
541,412
100.56M
US$ 148.830M
US$ 0.95
0.02 1.61
181,187
156.55M
US$ 147.940M
US$ 4.36
0.09 2.11
559,203
33.70M
US$ 146.930M
US$ 4.78
0.06 1.27
31,674
30.03M
US$ 143.540M
US$ 2.66
0.05 1.92
131,839
50.40M
US$ 134.060M
US$ 1.94
0.09 4.86
806,607
67.59M
US$ 131.120M
US$ 3.40
0.05 1.49
85,122
32.80M
US$ 111.520M
US$ 4.91
-0.07 -1.41
132,862
21.26M
US$ 104.390M
US$ 2.27
-0.02 -0.87
49,766
45.84M
US$ 104.060M
US$ 2.88
0.02 0.70
271,618
35.94M
US$ 103.330M
US$ 2.70
0.08 3.05
33,936
34.31M
US$ 92.640M
US$ 2.40
0.12 5.26
55,942
37.72M
US$ 90.530M
US$ 1.99
-0.01 -0.50
185,802
43.09M
US$ 85.750M
US$ 0.55
-0.0046 -0.83
374,091
145.47M
US$ 79.860M
US$ 1.60
0.06 3.56
15,252
49.50M
US$ 79.200M
US$ 4.49
0.02 0.45
37,708
17.64M
US$ 79.200M
US$ 12.10
0.04 0.33
15,378
6.27M
US$ 75.870M
US$ 4.59
-0.13 -2.75
86,832
16.39M
US$ 75.230M
US$ 1.21
0.12 11.01
789,071
59.34M
US$ 71.800M
US$ 0.90
-0.003 -0.33
28,745
77.89M
US$ 70.260M
US$ 2.32
0.22 10.48
26,338
30.25M
US$ 70.180M
US$ 2.49
0.03 1.22
2.83M
28.03M
US$ 69.790M
US$ 2.18
0.03 1.40
109,479
31.85M
US$ 69.430M
US$ 2.59
-0.01 -0.38
61,770
26.08M
US$ 67.550M
US$ 1.13
-0.01 -0.88
62,718
56.57M
US$ 63.920M
US$ 1.06
0.01 0.95
67,666
59.23M
US$ 62.780M
US$ 1.03
0.01 0.98
50,526
60.93M
US$ 62.760M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 0.45
0.05 13.67
102,894
139.01M
US$ 62.420M
US$ 1.91
0.01 0.53
16,823
29.25M
US$ 55.870M
US$ 1.09
-0.02 -1.36
325,953
49.57M
US$ 53.780M
US$ 1.64
-0.01 -0.61
523,432
32.02M
US$ 52.510M
US$ 3.24
0.00 0.00
19,647
16.04M
US$ 51.970M
US$ 1.38
0.07 5.34
39,289
37.10M
US$ 51.200M
US$ 20.01
0.00 0.00
0
2.54M
US$ 50.830M
C$ 0.45
0.01 2.30
23,100
113.40M
C$ 50.460M
C$ 0.20
0.00 0.00
500
247.78M
C$ 49.560M
US$ 0.83
0.03 3.75
464,705
55.19M
US$ 45.810M
US$ 0.47
-0.03 -5.80
168,301
95.97M
US$ 45.200M
US$ 1.63
-0.04 -2.11
52,763
26.67M
US$ 43.340M
US$ 2.45
0.07 2.94
22,647
17.54M
US$ 42.970M
US$ 4.01
0.41 11.39
3,316
10.64M
US$ 42.670M
US$ 0.10
-0.02 -13.79
877,477
417.59M
US$ 41.760M
US$ 0.70
0.03 4.10
115,268
57.89M
US$ 40.290M
US$ 6.02
0.04 0.67
57,195
6.55M
US$ 39.430M
US$ 3.83
1.93 101.58
2,137
10.07M
US$ 38.570M
C$ 0.41
0.00 0.00
0
93.38M
C$ 38.290M
US$ 0.96
-0.0011 -0.11
77,815
39.39M
US$ 37.660M
US$ 0.99
0.06 6.24
101,055
37.64M
US$ 37.190M
C$ 0.33
0.01 3.17
13,000
113.10M
C$ 36.760M
US$ 0.89
0.03 3.02
17,412
40.14M
US$ 35.640M
C$ 0.28
-0.02 -5.17
20,500
119.77M
C$ 32.940M
US$ 3.50
-0.18 -4.89
117,940
8.27M
US$ 28.940M
US$ 0.75
0.05 7.14
423,466
38.39M
US$ 28.790M
US$ 1.24
0.16 14.81
502,279
22.90M
US$ 28.400M
US$ 5.39
-0.02 -0.37
5,858
5.25M
US$ 28.300M
US$ 1.34
0.02 1.52
8,564
20.24M
US$ 27.120M
US$ 7.16
-0.18 -2.45
97,205
3.75M
US$ 26.850M
US$ 1.72
0.06 3.61
168,292
15.37M
US$ 26.440M
US$ 1.24
0.03 2.48
142,085
20.75M
US$ 25.730M
C$ 0.31
-0.01 -3.12
2,000
77.42M
C$ 24.000M
US$ 2.80
-0.10 -3.45
12,063
8.53M
US$ 23.880M
C$ 0.25
0.00 0.00
10,000
90.89M
C$ 22.720M
US$ 1.69
0.03 1.69
41,405
13.30M
US$ 22.450M
C$ 0.14
0.005 3.85
109,000
159.67M
C$ 21.560M
US$ 2.00
0.11 5.82
2,297
10.54M
US$ 21.080M
US$ 2.89
-0.46 -13.73
220,235
7.26M
US$ 20.980M
US$ 0.70
0.004 0.58
19,550
29.94M
US$ 20.870M
US$ 2.83
0.00 0.00
6,552
6.79M
US$ 19.220M
US$ 0.58
0.02 2.73
519,029
30.84M
US$ 17.890M
C$ 0.30
0.00 0.00
0
59.60M
C$ 17.880M
C$ 0.07
0.00 0.00
0
270.17M
C$ 17.560M
US$ 0.24
0.0095 4.12
392,397
72.19M
US$ 17.330M
US$ 0.39
-0.002 -0.51
287,108
43.62M
US$ 16.920M
US$ 1.01
-0.02 -1.94
111,413
16.64M
US$ 16.810M
US$ 0.32
-0.06 -16.67
4.07M
52.24M
US$ 16.610M
C$ 0.05
0.00 0.00
0
320.55M
C$ 16.030M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 0.55
0.01 1.85
38,308
27.52M
US$ 15.140M
US$ 1.42
0.03 2.16
53,267
10.63M
US$ 15.090M
US$ 0.55
-0.01 -1.81
5,296
25.04M
US$ 13.750M
US$ 1.90
0.06 3.26
18,977
7.09M
US$ 13.470M
US$ 0.59
-0.03 -4.28
236,693
22.45M
US$ 13.160M
US$ 2.10
0.02 0.96
83,937
5.89M
US$ 12.370M
US$ 0.61
0.00 0.00
0
19.01M
US$ 11.520M
US$ 0.56
0.00 0.00
0
20.63M
US$ 11.470M
US$ 0.47
0.06 13.42
5,244
24.39M
US$ 11.460M
US$ 0.35
0.01 2.97
23,203
31.93M
US$ 11.080M
C$ 0.05
0.00 0.00
55,000
217.73M
C$ 10.890M
US$ 2.53
0.0084 0.33
9,234
4.17M
US$ 10.550M
US$ 0.31
0.0001 0.03
27,247
31.90M
US$ 9.890M
US$ 0.56
-0.02 -3.28
136,736
17.23M
US$ 9.670M
US$ 0.51
0.09 21.40
797,466
18.34M
US$ 9.350M
US$ 0.42
0.0012 0.29
32,144
22.00M
US$ 9.130M
C$ 0.02
-0.005 -20.00
1.09M
451.63M
C$ 9.030M
US$ 4.42
0.08 1.80
1,166
2.04M
US$ 9.010M
C$ 0.09
0.00 0.00
0
100.02M
C$ 9.000M
US$ 5.88
0.37 6.72
5,076
1.48M
US$ 8.700M
US$ 0.52
0.05 9.67
485,497
15.58M
US$ 8.020M
US$ 1.27
0.00 0.00
0
6.24M
US$ 7.920M
US$ 0.71
0.03 4.41
18,216
11.07M
US$ 7.860M
US$ 1.25
-0.03 -2.34
48,321
6.00M
US$ 7.500M
US$ 0.10
0.00 0.00
0
73.90M
US$ 7.390M
US$ 3.22
0.02 0.62
38,993
2.22M
US$ 7.150M
US$ 2.34
0.09 4.00
59,139
2.71M
US$ 6.340M
US$ 0.94
-0.01 -1.32
79,049
6.67M
US$ 6.240M
US$ 0.94
-2.17 -69.77
21,003
6.63M
US$ 6.200M
US$ 0.41
-0.07 -14.58
226,117
14.59M
US$ 6.030M
US$ 1.19
-0.01 -0.83
23,502
4.81M
US$ 5.720M
C$ 0.11
0.00 0.00
0
48.23M
C$ 5.060M
US$ 0.31
0.00 0.00
0
15.85M
US$ 4.920M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
US$ 0.35
-0.0022 -0.63
53,852
13.96M
US$ 4.870M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
C$ 0.05
0.00 0.00
0
101.29M
C$ 4.560M
US$ 0.36
0.00 0.00
0
11.88M
US$ 4.280M
US$ 0.93
0.04 4.71
45,288
4.37M
US$ 4.080M
US$ 0.67
-0.0067 -1.00
4,061
5.85M
US$ 3.900M
US$ 0.78
0.00 0.00
0
4.85M
US$ 3.780M
US$ 1.12
0.04 3.70
266,914
3.14M
US$ 3.520M
US$ 1.85
0.08 4.52
24,679
1.77M
US$ 3.280M
US$ 3.30
0.24 7.84
3,891
980,321
US$ 3.240M
US$ 1.70
0.00 0.00
0
1.82M
US$ 3.090M
US$ 0.32
-0.02 -4.48
40,718
8.00M
US$ 2.560M
US$ 0.11
-0.0024 -2.21
23,992
21.04M
US$ 2.230M
US$ 3.67
0.32 9.55
2.09M
536,908
US$ 1.970M
US$ 0.17
0.00 0.00
0
10.59M
US$ 1.800M
US$ 1.00
0.40 66.67
1,222
1.78M
US$ 1.780M
US$ 0.68
0.0097 1.45
31,576
2.46M
US$ 1.670M
US$ 0.47
0.00 0.00
0
3.20M
US$ 1.520M
US$ 0.08
0.00 0.00
0
16.67M
US$ 1.370M
US$ 0.04
-0.05 -55.56
6,325
29.91M
US$ 1.200M
US$ 1.24
-0.09 -6.44
35,971
962,637
US$ 1.190M
US$ 1.99
-0.22 -9.95
210,166
552,854
US$ 1.100M
US$ 0.20
0.00 0.00
0
5.24M
US$ 1.050M
US$ 0.28
-0.005 -1.79
53,016
3.73M
US$ 1.030M
US$ 0.009
0.00 0.00
0
96.71M
US$ 870K
US$ 0.09
0.00 0.00
0
7.26M
US$ 653K
C$ 0.01
0.00 0.00
10,219
59.81M
C$ 598K
US$ 1.20
0.00 0.00
0
418,049
US$ 502K
US$ 0.31
-0.05 -14.62
4.37M
729,980
US$ 226K
US$ 0.03
0.0055 20.75
379.44M
2.05M
US$ 66K
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
6.39M
US$ -
US$ 0.00
-0.0003 -100.00
16.75M
855.04M
US$ -
C$ 0.50
0.00 0.00
45,336
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


Medtronic: New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved

Latest approval expands Medtronic CGM portfolio in the U.S. GALWAY, Ireland, April 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the MiniMed™ 780G system. With this approval, the MiniMed™ 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal... Read more


Tempus AI Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

CHICAGO / Apr 18, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals... Read more


Edwards Lifesciences: Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue

CAIRO / Apr 18, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA... Read more


bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection. SAN ANTONIO / Apr 17, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced implementation of key efficiency measures for its flagship product, CyPath® Lung,... Read more


Bruker Introduces nVista 2P Miniature Microscope

Revolutionizing Neural Circuit Imaging in Freely Behaving Animal Research SAN JOSE, Calif. / Apr 17, 2025 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data... Read more


DarioHealth Collaborates with Leading National Benefit Plan Administrator to Offer Cardiometabolic Solution including a GLP-1 Support Program to Employers

Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025 NEW YORK, April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital... Read more


Nano-X Imaging Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X

First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indications Enhanced imaging system features sleek design with smaller footprint; simplified ‘plug and play’ installation process System design enables software upgrades and new capabilities to be added remotely following future regulatory clearances PETACH TIKVA, Israel, April 17, 2025 (GLOBE NEWSWIRE)... Read more


United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney Damage

Regulatory milestone enables commercial expansion into high-need international market 10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (Microalbumin) Test... Read more


Agilent Technologies Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA® therapy SANTA CLARA, Calif. / Apr 17, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible... Read more


electroCore: gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Ament of Cherry Creek Neurology presented... Read more


CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA... Read more


Autonomix Medical Granted New European Patent for Proprietary Catheter-Based Technology

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology  Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases... Read more


Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced... Read more


Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont., April 16, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced the completion of a secondary private sale of 73.1 million shares of Xtant... Read more


Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1 Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increase Reported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis... Read more


Spectral Medical Completes Tigris Trial Enrollment

157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the completion of full enrollment in the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use... Read more


Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

Bruker and RECIPE are pioneering the high-throughput ‘chrom-free’ ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays MUNICH / Apr 16, 2025 / Business Wire / Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic... Read more


Hyperfine Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices

Real-world study will assess clinical utility and patient experience across diverse neurological conditions to support adoption of AI-powered portable MRI systems in the office setting. GUILFORD, Conn. / Apr 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system, first approved... Read more


RadNet to Acquire iCAD to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries With iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate... Read more


Illumina and Tempus AI partner to drive the future of precision medicine through genomic AI innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation.... Read more


Tivic Health Systems Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia

FREMONT, Calif. / Apr 15, 2025 / Business Wire / Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™.... Read more


Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. ("Okava"), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy... Read more


Vivos Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™

Kennewick, WA, April 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide Therapy™, an FDA-designated Breakthrough Device for the treatment of solid tumors. The latest results highlight both technical progress and growing clinical validation. This update builds upon the initial results released in February 2025, which confirmed the safety of RadioGel®... Read more


Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market

Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury New and improved features streamline user experience for greater control, engagement, and confidence during walking in everyday environments MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology... Read more


Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform to select targeted patient cohorts to significantly de-risk clinical trials PITTSBURGH, April 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has made significant progress along the... Read more


FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and O

SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1 and older. This makes Ceribell... Read more


Profound Medical AUA 2025 Investor Event Agenda

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual... Read more


908 Devices Announces Preliminary First Quarter 2025 Financial Results

At least 55% reported revenue growth from continuing operations compared to prior year BOSTON / Apr 15, 2025 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025... Read more


Bluejay Diagnostics Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit... Read more


QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands VENLO, Netherlands / Apr 15, 2025 / Business... Read more


Milestone Scientific Reports Year-End 2024 Financial Results and Reports Strong Outlook for 2025

Reports expansion of CompuFlo® Epidural System across additional pain management clinics and ambulatory surgery centers following Medicare price assignment in multiple U.S. states ROSELAND, N.J., April 15, 2025 (GLOBE NEWSWIRE) --  Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the... Read more


Biomerica Reports Third Quarter Fiscal 2025 Financial Results

Total Revenue Increases 10% Year-Over-Year Delivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2025 ended February 28, 2025. Key Highlights: 1. Fortel® PSA Screening Test... Read more


NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”

Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional antibodies SARASOTA, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc. (the “Company”) (Nasdaq: NAYA), a healthcare services fertility company focused... Read more


Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results Total revenue is expected to be between $11.8 million and $12.0... Read more


Kestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results

KIRKLAND, Wash., April 14, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2025, which ended January 31, 2025. Recent Highlights Q3 FY25 revenue and gross margin were in line with the preliminary estimated financial results previously disclosed in the company’s IPO prospectus. Generated revenue of $15.1... Read more


Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is pleased to announce that the United States Patent and Trademark Office (USPTO) has officially granted its patent titled "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD)." This milestone further... Read more


Edwards Lifesciences SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

IRVINE, Calif. / Apr 14, 2025 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3 system is the world's first approved... Read more


Exact Sciences: JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity MADISON, Wis. / Apr 14, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX... Read more


Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock

TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The... Read more


Theralase Technologies Closes Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered... Read more


Lucid Diagnostics Announces Closing of Public Offering of Common Stock

NEW YORK, April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares,... Read more


Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 14,... Read more


Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as monotherapy in patients with histologically confirmed melanoma and positive m... Read more


PROCEPT BioRobotics Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas

SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE.... Read more


MiMedx to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. “MIMEDX’s ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be... Read more


Sanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

FORT WORTH, TX, April 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that management will present at the Planet MicroCap Showcase: VEGAS 2025 in partnership... Read more


Intuitive: U.S. FDA clears first stapler designed for single-port robotic surgery

SUNNYVALE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) cleared the company’s fully wristed SP SureForm 45 stapler for use with its da Vinci SP surgical system in thoracic, colorectal, and urologic procedures. Like its multiport counterparts, the SP SureForm 45 features... Read more


Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12

NEW YORK / Apr 10, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, provided preliminary first quarter 2025 sales results and announced that it will host an analyst and investor event in New York City on June 12, 2025. Establishment Labs’ preliminary unaudited revenue for the first quarter of 2025 is expected... Read more


DexCom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes. Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes. For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system. SAN DIEGO / Apr 10, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the... Read more


Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025

Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView® Minimal Residual... Read more